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Identification of a subpopulation of MeCCNU resistant cells
in previously untreated Lewis lung tumours
T.C. Stephens, K. Adams & J.H. Peacock
Radiotherapy Research Unit, Institute ofCancer Research, Sutton, Surrey, UK.
Summary A variety of experimental endpoints including excision cell survival, lung colony curability,
tumour regrowth delay and i.m. tumour curability following MeCCNU alone and combined with y-radiation,
were used to define the MeCCNU cell survival curve down to "tumour cure" level in previously untreated
i.m. Lewis lung tumours.
The survival curve was found to be biphasic, the tumour cells being markedly resistant to MeCCNU at
high doses of the drug. Below 10mgkg-I the survival curve was exponential through the origin with a DIo of
approximately 2mgkg-1, while above 15mgkg-1 the D,o was -.25mgkg-1. From linear extrapolation of the
terminal part of the cell survival curve to zero drug dose, it appeared that about 1 in 105 (or 0.001%) of
tumour cells were resistant to MeCCNU.
The nitrosoureas BCNU, CCNU and MeCCNU,
when administered in large single doses, appear to
be amongst the most effective of cytotoxic agents
against a range of experimental tumours in vivo
(e.g. Lewis lung carcinoma, B16 melanoma, KHT
sarcoma, L1210 leukaemia), as judged by cell
survival, regrowth delay and "tumour cure"
endpoints (Blackett et al., 1975; Mayo et al., 1972;
Schabel, 1976; Mulcahy, 1982).
However, in a clinical context, these nitrosoureas
do not appear to have fulfilled the promise that
might have been expected from pre-clinical thera-
peutic studies. The reason for this is not clear,
although it may sometimes be due to rapid
development of tumour cell resistance to this class
of cytotoxic agents. Development of resistance to
nitrosoureas has been reported with several experi-
mental tumours, including the Lewis lung
carcinoma (Schabel, 1976) and B16 melanoma
(Griswold et al., 1974), especially when the agents
are administered by the clinically relevant regime of
repeated moderate doses.
In this paper we explore the response of
previously untreated Lewis lung tumours to
MeCCNU. The experiments allow us to construct
the "complete" MeCCNU cell-survival curve down
to "tumour cure" level, and to comment on the
extent to which MeCCNU resistance occurs in this
tumour.
Materials and methods
Mice and tumour
C57B1/Cbi mice (20-25g) were obtained from the
Institute of Cancer Research breeding centre. Lewis
lung carcinoma (LL) was maintained in these mice
by i.m. transplant of tumour brei, bilaterally into
the gastrocnemius muscles (Steel & Adams, 1975).
In excision cell survival experiments tumours
were used when they weighed between 0.15 and
0.25 g, and in growth delay and "tumour cure"
studies they were used at various sizes from <0.1
to 1.2g.
Cytotoxic drug and radiation treatments
MeCCNU (obtained from the National Cancer
Institute) was prepared as a stock solution at a
concentration of 20mgml-1 in DMSO, and stored
in 0.5ml aliquots, at -20°C. For i.p. injection into
animals, MeCCNU at 1 mgml1 was prepared by
diluting an 0.5ml aliquot of frozen stock 1 in 20
with 5% Tween 80 in PBSA. The diluted drug was
always used within 15min of preparation.
In the radiation "top-up" experiments, 60Co-y-
irradiation was administered locally to intra-
muscular tumours of conscious air-breathing mice,
using the animal constraining jig arrangement
described in Figure 1. To locally irradiate hypoxic
tumours, mice were anaesthetized with Saffan, the
blood supply to the tumour bearing leg was
temporarily clamped with a loop of nylon cord and
that leg was then locally irradiated using the
constraining jig described by Steel et al. (1978). For
all irradiations, the dose-rate was approximately
3 Gymin-1. Dosimetry was performed using a
Baldwin-Farmer substandard dosimeter.
Preparation ofcell suspensions
Tumour cell suspensions for in vitro cell survival
assessment and in vivo lung colony assays, were
prepared from aseptically excised tumour tissue by
a trypsinization procedure described in detail by
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Figure 1 Perspex jig for local 60Co-y-irradiation of i.m. tumours. Mice were located in 4 vertically stacked,
horizontal tubular chambers (7.5cm long x 2.5cm dia.). The tumour-bearing leg of each animal was gently
pulled through a slot 1 cm wide located near the rear of the chamber, and fixed by sticking plaster to a
perspex platform, so that the tumour was immediately behind a 5cm thick perspex radiation build-up sheet.
The entrance of the chamber was closed with a perspex bung. For irradiation, the jig was located on a base
so that each tumour was 30cm from a tubular cobalt source (15cm long x 9.5mm dia.). The body of each
mouse was shielded behind 13.5cm oflead, and scatter was minimized by a lead wedge attached to the side of
thejig.
Stephens & Peacock (1978). Briefly, this involved
pre-trypsinization of well chopped tumour tissue for
15min without shaking to remove dead and
damaged tumour cells, followed by a 20min main
treatment with fresh trypsin/DNase solution, with
continuous gentle agitation. At the end of this
treatment, loosely adhering clumps of cells were
dispersed with 10 vigorous shakes and any
remaining clumps of cells were removed by filtering
the digest through 35 gum polyester mesh. The single
cells were washed and resuspended in Ham's F12
culture medium containing 20% Donor calf serum,
for counting either by haemocytometer or Coulter
Counter (Model ZBI). The viable tumour cell yield
from LL tumours was 8.5 x 10'7cellsg-
(s.d. =2 x 107).
Cell survival assessment in vitro
The soft-agar colony assay developed by Courtenay
(1976) was used to measure tumour cell survival in
trypsinized cell suspensions. When counting cell
suspensions prior to plating (or for lung colony
assays), care was taken to distinguish between host-
derived cells and tumour cells (Stephens et al.,
1978). The host cells in these tumours are mainly
monocytes, forming a distinct subpopulation of
diameter 6 to 8.5,um, whereas tumour cells are
greater than 9pum in diameter (see Figure 3). When
counting colonies, care was also taken to
distinguish between tumour and host-derived
colonies (Stephens et al., 1978). The criterion for a
tumour colony was .50 tightly packed cells and
the mean tumour cell plating efficiency
(PE=number of tumour colonies scored/number of
tumour cells plated) of untreated controls was 0.51
(s.d. =0.14). The effect of drug treatment was
expressed as the fraction of surviving tumour cells
per tumour, calculated as:
number of colony-forming tumour cells per treated
tumour/number of colony-forming tumour cells per
control tumour.
Lung-colony assay
The lung colony assay has been described in detail
for the LL tumour by Steel & Adams (1977). In
this study all implants consisted of viable cells plus
106 heavily irradiated feeder cells and 106 15gum
diameter plastic microspheres. The lung cloning
efficiency (CE=number of lung colonies scored per
lung/number of tumour cells injected per mouse) of
untreated tumour cells was in the range 3 x 10-4 to
10-3.
Measurement oftumour growth delay
Intramuscular tumours of untreated controls and of
drug or radiation treated mice were measured
sequentially 2 or 3 times per week, by passing
unshaved tumour bearing legs through holes of
known diameter, in a perspex disc. Leg diameters
were converted to tumour wt using a calibration
curve relating measured leg diameter to dissected
tumour wt. Since some tumours did not shrink
significantly after treatment, tumour volume
responses were determined by measuring the time
to regrow to 4 x their pretreatment volume (T4X),
and then calculating growth delays as (median T4X
of treated tumours) - (median T4X of untreatedTUMOUR RESISTANCE TO MeCCNU 79
controls). For tumours that were not palpable
(<0.1 g) at the time of treatment, growth delay was
determined at a target size of 0.5g.
Criterionfor "tumour cure"
"Tumour cure" was deemed to have been achieved
if a leg which had been shown by measurement to
contain a tumour, shrank to the size of a normal
leg (6mm) and remained without sign of any
tumour regrowth for more than 50 days. This time
is approximately that required for a single
untreated cell, implanted i.m. with 106 irradiated
feeder cells, to yield a 1 g tumour. As a safeguard
against false-positive cure results in the experiment
where tumours were treated before they became
palpable, the untreated controls and low-dose, non-
curative treatment groups, were all carefully obser-
ved and each found to have 100% takes.
Results
Excision cell survivalfollowing MeCCNU treatment
Mice bearing i.m. LL tumours weighing -0.2g
were treated with a range of doses of MeCCNU
and excision cell survival assays were performed
24h later. The resultant survival curve is shown in
Figure 2.
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Figure 2 MeCCNU dose-survival curve of 0.2gLL
tumours obtained using an excision assay.
Survival curve parameters, derived by least-
squares regression analysis, are: D,o (dose to reduce
survival by 1 decade)= 1.79mgkg-' (95% CL
1.68-1.93) and n (extrapolation number)=0.90
(95% CL 0.66-1.22). The data suggest that LL
tumours are highly sensitive to MeCCNU and since
the LD,O (lethal dose to kill 10% of mice) of
MeCCNU in our mice is >40mgkg-1, such
tumours should be easily cured at high drug doses,
providing that the survival curve is simply
exponential (SF= l0-DOse/DlO). Unfortunately this
cannot be tested directly above 8mgkg-1, since the
in vitro survival assay is impractical when high
numbers of cells need to be plated. However, the
MeCCNU dose required to cure 0.2g tumours can
be predicted from the excision cell survival data
and then compared with directly measured tumour
cure rates.
Prediction oftumour cure by MeCCNU
In order to predict "tumour cure rates" by
MeCCNU, it is necessary to know the inherent
sensitivity of tumour cells to the drug (Figure 2)
and the maximum number of cells which need to be
killed for a tumour to be cured (i.e. the number of
stem cells per tumour).
Tumour stem cellularity was estimated using the
cell size data shown in Figure 3. This is a typical
size profile for a trypsinized LL tumour suspension.
Distinct populations of host cells (peak volume
-200,u3) comprising 15% of total nucleated cells,
and tumour cells (peak volume -800p3) can be
seen. From this, and 9 other cell size profiles, a
mean value for tumour cell volume of 1090 3 was
obtained by integrating the area under the tumour
cell peak. If tumour tissue has unit density and
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Figure 3 Size profile of a typical cell suspension
obtained from an untreated LL tumour. Cell sizes
were measured using a Coulter counter, and analysed
using a multichannel analyser and dedicated micro-
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consists entirely of tumour cells, then an 0.2g
tumour will contain not more than 1.8 x 108 cells.
However, allowing for the considerable
contribution to tumour volume of host cells, blood
vessels, connective tissue and necrosis, a more
reasonable estimate would be 108 tumour cells/0.2g
tumour. It is also reasonable to assume that most
LL tumour cells possess stem cell potential and can
thus regrow a tumour. This is supported by the
high in vitro PE of LL tumour cells (up to 70%),
the very low TD50 (cell dose to give 50% takes
when implanted i.m.) of <3 cells (Steel & Adams,
1975) and the lack of histological evidence of
differentiation in these tumours. Assuming that all
cells are clonogenic, and that Poisson's cure
statistics apply (cure probability P=e-m, where
m=mean number of survivors per tumour), then
50% of tumours will regrow when 0.69 cells survive
per tumour.
The drug dose required to achieve this (tumour
cure dose, 50% TCD50) with tumours containing
108 cells will be about 15mgkg-1. This TCD50 is
well below the LD10 for drug toxicity.
Direct measurement of "tumour cure" and regrowth
delay
Groups of 10-15 tumour bearing mice were treated
with various doses of MeCCNU from 5-40mgkg-1
and measured regularly thereafter. The experiment
was repeated with four different mean tumour sizes
at the time of drug treatment, <0.1 g (not
palpable), 0.2g, 0.35g and 1.2g. "Tumour cure
rates" are plotted in Figure 4 and growth delay in
Figure 5. The data in Figure 4 show that higher
drug doses are required for cure than predicted
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Figure 5 Growth delay curves for LL tumours
treated with MeCCNU at various sizes (symbols as in
Figure 4).
sizes "cures" were very infrequent. The regrowth
delay data in Figure 5 suggest that this might be
due to the presence within these tumours of a
resistant subpopulation of tumour cells. The growth
delay curves at each treatment size are all markedly
biphasic, becoming less steep above 15-20mgkg-1
of MeCCNU. There is also a tendency for the
smaller tumours to experience longer growth delays
than the larger tumours, although the terminal
slopes at each size do not seem to differ
significantly. Experiments were therefore devised in
an attempt to confirm the apparent low-dose
sensitivity of LL to MeCCNU and the apparent
resistance at high doses.
Cell sensitivity assessed by the lung-colony assay
from cellular sensitivity and tumour The lung-colony assay was used in an
;y calculations. Up to 40% cures could be unconventional way to confirm in vivo the drug
with small tumours (<0.2g), but only at sensitivity measured at low MeCCNU doses by the
U doses >25mgkg-1. At larger tumour in vitro excision cell survival assay. Various
numbers of trypsinized tumour cells, prepared from
untreated LL tumours were injected i.v. into
recipient mice and became trapped as pulmonary
emboli. Twenty-four hours later, before significant
proliferation had occurred, the mice were treated
with a range of doses of MeCCNU and the survival
-iA of emboli was determined from the number of
|,;\ /$8-o macroscopic lung colonies present 14 days later.
. y / \, a The survival data obtained using this technique are £ /*-------- i - -* presented below in Figure 7 (open circles). Survival 0 10 20 30 40 curve parameters derived by least squares regression
MeCCNU dose (mg kg') analysis are D10=2.13mg/kg (95% CL 1.63 to
"Cure" curves for LL tumours treated with 3.05), n= 1.23 (95% CL 0.50 to 3.00). The results
IU at various sizes, (A)<0.1 g; (0) 0.2g; (O) are not significantly different from those obtained
Lnd (V) 1.2g. The solid "cure curve" was with the excision cell survival assay (shown in
d by extrapolating the MeCCNU survival Figure 2). Limitations on the number of cells that
own in Figure 2 to cure levels, and assuming can be injected i.v. restrict the sensitivity of this
nours contain 108 clonogenic cells. assay to SFs>2 x 10-3.
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)eriment was designed to measure tumours (TCD50) is inversely related to the dose of
dose of MeCCNU to cure MeCCNU which was given. The TCD50 values
cuLLa ri
w were used to estimate the extent of radiation-
with 7t5m 15 or 40mgkgt induced cell kill from a radiation cell survival curve.
It was assumed that there was no marked ity-four hours later, they were interaction between radiation and MeCCNU, e.g.
with graded doses of 60Co-y-rays the radiation of the residual cells surviving
tumour cure rates" were scored. MeCCNU was similar to that of previously
ygen status of cells surviving untreated tumours. This is not quite true; there is a known, tumours were irradiated marked synergistic interaction between MeCCNU
reathing and clamped conditions. and radiation when administered simultaneously
presented in Figure 6, show as but this is substantially reduced when they are
0 0- separated by 24h (manuscript in preparation). The
'o- ~chosen radiation survival curve parameters were Do
o (oxic)
= 1.3 Gy, n (oxic)
= 5, Do (hypoxic)= 5 and
X0 o / hypoxic fraction = 10%, taken from Stephens et al.
A / (1978) and Shipley et al. (1983). To obtain the log
cell kill due to MeCCNU, the cell kill attributable
to radiation was subtracted from the total log cell
_,_____________________ 0kill required to cure an 0.2 g tumour (Table I).
10 20 30 40 The MeCCNU cell survival curve deduced from
the radiation "top-up" experiment is shown in
Figure 7. The data obtained with 7.5mgkg-1
MeCCNU appear to confirm the excision cell
,b' ,' survival and lung colony measurements of cell
O/ / killing at low MeCCNU doses and at higher doses
o A/^ Ab zO the curve is markedly biphasic as suggested by the
I/ I-,' growth delay data (Figure 5) but due to the indirect
Az = -' nature of the estimates of cell-survival at high
10 20 30 40 MeCCNU doses, the terminal D10 value cannot be
Radiation dose (Gy) quoted very precisely. Although there are
ion "cure curves" for 0.2g LL differences in the ratios of TCD air: clamped at
ias previously been treated with different MeCCNU doses, Figure 7 shows that the
the protocol for radiation "top-up" cell survival estimated from either radiation
Ixt. (a) air-breathing irradiation, (b) condition does not significantly differ. Least
tumour) irradiation. MeCCNU squares regression over the MeCCNU dose range
), 15 (A) and 40 (0) mgkg-1. 15-40mgkg-1 yields a D1o value of 26mgkg-1
Table I Radiation "top-up" results
MeCCNU Radiation Radiation MeCCNU
dose Radiation TCD50 equivalent equivalent
(mgkg 1) conditions (Gy)a log killb log killc
7.5 a/b 34.2 4.0 4.2
hyp 34.4 3.0 5.2
15 a/b 20.0 2.5 5.7
hyp 28.2 2.4 5.8
40 a/b 9.2 1.3 6.9
hyp 22.9 1.8 6.4
aComputer fit by method of Suit et al. (1964).
bRadiation equivalent log kill= -log10 (radiation equivalent SF).
cMeCCNU equivalent log kill=total log kill required to cure 50%
of tumours - Radiation equivalent log kill.
Total log kill required to cure 50% of tumours = -logl0
(0.69/108) 8.2 logs.
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Figure 7 The "complete" in vivo MeCCNU dose-
survival curve for 0.2g i.m. LL tumours, down to
"cure" levels: solid line (0 to 8mgkg-1), soft agar
excision survival curve from Figure 2. (0) in vivo
sensitivity of single LL cells trapped in pulmonary
emboli and assayed by lung-colony formation. (A, [1)
sensitivity of i.m. LL tumours derived from the
radiation cure data for air-breathing (A) and hypoxic
(C) conditions presented in Figure 6. See text for
experimental details.
(95% CL 12-40) and the incidence of resistant cells
is 1- in 105.
Discussion
We have used a variety of approaches in order to
define the "complete" MeCCNU survival curve in
previously untreated i.m. LL tumours. At low drug
doses (<8mgkg-1) cell sensitivity was measured
directly using an excision cell survival assay and a
modification of the lung colony assay. The majority
of the tumour cells appeared by these assays to be
highly drug sensitive (D10 % 2mgkg- ). If this
sensitivity extended to all tumour cells, LL tumours
should easily be cured at MeCCNU doses well
below the LD1O for C57B1 mice. However, the
observed low curability even at very high
MeCCNU doses, is not consistent with this model,
but suggests that LL tumours may contain a small
subpopulation (- 1 in 105) of much more resistant
cells. Other evidence for drug resistance at high
MeCCNU doses comes from the strongly biphasic
nature of the growth delay response in LL tumours
and the radiation "top-up" experiment. In this
experiment, the effect of high MeCCNU doses was
estimated indirectly by measuring the additional
radiation-induced cell killing required to "cure" the
tumours. Assumptions had to be made concerning
the clonogenic cell content of the tumours before
treatment and the radiosensitivity of MeCCNU
survivors to the "top-up" gamma-ray dose. The
validity of these assumptions was tested by
performing the "top-up" experiment with a low
MeCCNU dose (7.5mgkg-1) which had been used
in direct excision cell survival assays. The
agreement between direct assay and "top-up" data
was reasonable, so that at higher MeCCNU doses
it was possible to predict a survival curve with a
D1o at least 10 times greater than that measured at
low doses (i.e. - 25mgkg 1). However, the number
of MeCCNU resistant cells constituted only
-0.001% of all cells in previously untreated
tumours.
From the studies presented here it is not possible
to comment on the nature, or origin, of the
resistance leading to the biphasic MeCCNU
survival curve, although this has been examined,
and will be described later. Apart from the work of
Schabel (1976) and Griswold et al. (1974), utilizing
multiple treatment regimes, we are aware of only
one other bifunctional nitrosourea survival curve
which appears to demonstrate drug resistance in
previously untreated tumours. Mulcahy et al. (1982)
reported a biphasic excision cell survival curve for
KHT tumours treated with BCNU. Although the
slope of the resistant tail cannot be evaluated, it
would appear that <1 in 104 cells exhibited
resistance to BCNU. Whether the poor clinical
performance of the nitrosoureas is due to a
tendency for rapid development of drug resistance
is not clear.
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